Arrow Therapeutics selects a further Hepatitis C compound A-689
17-Jan-2007
Once again A-689 originates from Arrow's focused chemical library and was optimised inhouse. According to the company, the compound has shown highly potent activity in the replicon assay and has an excellent therapeutic index and good pharmacokinetic properties. Phase I trials on A-689 are planned for the second half of 2007.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.